{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.81","upperLimit":"10.59","value":"4.14"},{"groupId":"OG001","lowerLimit":"13.71","upperLimit":"22.09","value":"14.63"},{"groupId":"OG002","lowerLimit":"6.25","upperLimit":"20.05","value":"10.03"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"Dose Expansion. Overall survival is defined as the time from randomization until death from any cause, and is measured in the intent-to-treat population.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dose Escalation: Level 1 dose of 80 mg enzalutamide (orally), with standard doses of cisplatin and gemcitabine via intravenous (IV).","id":"OG000","title":"Dose Escalation: Level 1 Dose"},{"description":"Dose Escalation: Level 2 dose of 160 mg enzalutamide (orally) with standard dose of cisplatin and gemcitabine via intravenous (IV).","id":"OG001","title":"Dose Escalation: Level 2 Dose"},{"description":"Dose Expansion: Enzalutamide at MTD (160 mg) with standard doses of cisplatin and gemcitabine.","id":"OG002","title":"Dose Expansion"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 24 Months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}